Incyte's Eczema Drug Ruxolitinib Works in a Late-Stage Clinical Trial
Results of a phase 3 clinical trial dubbed TRuE-AD2 showed that Incyte's (NASDAQ: INCY) ruxolitinib cream helped patients with atopic dermatitis, an autoimmune disease commonly referred to as eczema. Shares of Incyte were up about 1% on the news in early afternoon trading Tuesday.
After eight weeks of treatment, both the 0.75% and 1.5% doses helped more patients reach an Investigator's Global Assessment (IGA) score of clear or almost clear with at least a two-point improvement in IGA compared to patients using the base cream without the medication.
Incyte didn't disclose the number of patients who met the goal in each treatment group. As biotech companies are apt to do, it's saving the more-detailed data for an upcoming scientific meeting. Additional data from another phase 3 clinical trial in patients with eczema (TRuE-AD1) is also expected this quarter.
Source Fool.com
